MET amplification, protein expression, and mutations in pulmonary adenocarcinoma

Lung Cancer

Volumn 90, Issue 3, 2015, Pages 381-387

  Park, Seongyeol ^a   Koh, Jaemoon ^a   Kim, Dong Wan ^a   Kim, Miso ^a   Keam, Bhumsuk ^a   Kim, Tae Min ^a   Jeon, Yoon Kyung ^a   Chung, Doo Hyun ^a   Heo, Dae Seog ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Adenocarcinoma; Gene amplification; Gene expression; MET; Mutation; Non small cell lung carcinoma

Indexed keywords

SCATTER FACTOR RECEPTOR; MET PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; FOLLOW UP; GENE EXPRESSION; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-MET; YOUNG ADULT;

EID: 84949228223     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.10.022     Document Type: Article

References (33)

1. Cardarella S., Johnson B.E. The impact of genomic changes on treatment of lung cancer. Am. J. Respir. Crit. Care Med. 2013, 188:770-775.
2. Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., Comoglio P.M. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989, 339:155-156.
3. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
4. Gherardi E., Birchmeier W., Birchmeier C., Vande Woude G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 2012, 12:89-103.
5. Edakuni G., Sasatomi E., Satoh T., Tokunaga O., Miyazaki K. Expression of the hepatocyte growth factor/c-met pathway is increased at the cancer front in breast carcinoma. Pathol. Int. 2001, 51:172-178.
6. Otte J.M., Schmitz F., Kiehne K., Stechele H.U., Banasiewicz T., Krokowicz P., Nakamura T., Folsch U.R., Herzig K. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 2000, 61:237-246.
7. Sweeney P., El-Naggar A.K., Lin S.H., Pisters L.L. Biological significance of c-met over expression in papillary renal cell carcinoma. J. Urol. 2002, 168:51-55.
8. Wu J.G., Yu J.W., Wu H.B., Zheng L.H., Ni X.C., Li X.Q., Du G.Y., Jiang B.J. Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma. BMC Res. Notes 2014, 7:6.
9. Yano S., Nakagawa T. The current state of molecularly targeted drugs targeting HGF/Met. Jpn. J. Clin. Oncol. 2014, 44:9-12.
10. Lutterbach B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., Gibbs J.B., Pan B.S. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007, 67:2081-2088.
11. Cappuzzo F., Marchetti A., Skokan M., Rossi E., Gajapathy S., Felicioni L., Del Grammastro M., Sciarrotta M.G., Buttitta F., Incarbone M., Toschi L., Finocchiaro G., Destro A., Terracciano L., Roncalli M., Alloisio M., Santoro A., Varella-Garcia M. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 2009, 27:1667-1674.
12. Go H., Jeon Y.K., Park H.J., Sung S.W., Seo J.W., Chung D.H. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J. Thorac. Oncol. 2010, 5:305-313.
13. Beau-Faller M., Ruppert A.M., Voegeli A.C., Neuville A., Meyer N., Guerin E., Legrain M., Mennecier B., Wihlm J.M., Massard G., Quoix E., Oudet P., Gaub M.P. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J. Thorac. Oncol. 2008, 3:331-339.
14. Chen Y.T., Chang J.W., Liu H.P., Yu T.F., Chiu Y.T., Hsieh J.J., Chen Y.T., Chen Y.R., Wu H.D., Huang S.F. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment. J. Thorac. Oncol. 2011, 6:2027-2035.
15. Dziadziuszko R., Wynes M.W., Singh S., Asuncion B.R., Ranger-Moore J., Konopa K., Rzyman W., Szostakiewicz B., Jassem J., Hirsch F.R. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J. Thorac. Oncol. 2012, 7:340-347.
16. Onitsuka T., Uramoto H., Ono K., Takenoyama M., Hanagiri T., Oyama T., Izumi H., Kohno K., Yasumoto K. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J. Thorac. Oncol. 2010, 5:591-596.
17. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
18. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W.C., Yu C.J., Gazdar A., Pass H., Rusch V., Gerald W., Huang S.F., Yang P.C., Miller V., Ladanyi M., Yang C.H., Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20932-20937.
19. Tsuta K., Kozu Y., Mimae T., Yoshida A., Kohno T., Sekine I., Tamura T., Asamura H., Furuta K., Tsuda H. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J. Thorac. Oncol. 2012, 7:331-339.
20. Sun W., Song L., Ai T., Zhang Y., Gao Y., Cui J. Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer. J. Biomed. Res. 2013, 27:220-230.
21. Nakamura Y., Niki T., Goto A., Morikawa T., Miyazawa K., Nakajima J., Fukayama M. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 2007, 98:1006-1013.
22. Park S., Choi Y.L., Sung C.O., An J., Seo J., Ahn M.J., Ahn J.S., Park K., Shin Y.K., Erkin O.C., Song K., Kim J., Shim Y.M., Han J. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol. Histopathol. 2012, 27:197-207.
23. Guo B., Cen H., Tan X., Liu W., Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PLoS One 2014, 9:e99399.
24. Kong-Beltran M., Seshagiri S., Zha J., Zhu W., Bhawe K., Mendoza N., Holcomb T., Pujara K., Stinson J., Fu L., Severin C., Rangell L., Schwall R., Amler L., Wickramasinghe D., Yauch R. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006, 66:283-289.
25. Onozato R., Kosaka T., Kuwano H., Sekido Y., Yatabe Y., Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J. Thorac. Oncol. 2009, 4:5-11.
26. Spigel D.R., Ervin T.J., Ramlau R.A., Daniel D.B., Goldschmidt J.H., Blumenschein G.R., Krzakowski M.J., Robinet G., Godbert B., Barlesi F., Govindan R., Patel T., Orlov S.V., Wertheim M.S., Yu W., Zha J., Yauch R.L., Patel P.H., Phan S.C., Peterson A.C. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2013, 31:4105-4114.
27. Spigel D.R., Edelman M.J., O'Byrne K., Paz-Ares L., Shames D.S., Yu W., Paton V.E. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. ASCO Annu. Meet. Abstr. 2014, 8000.
28. D.R. Camidge, S.I. Ou, G. Shaprio, G.A. Otterson, L.C. Villaruz, M.A. Villalona-Calero, A.J. Iafrate, M. Varella-Gracia, S. Dacic, S. Cardarella, W. Zhao, L. Tye, Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC), ASCO Annual Meeting. Abstract 8001, 2014.
29. Tanaka A., Sueoka-Aragane N., Nakamura T., Takeda Y., Mitsuoka M., Yamasaki F., Hayashi S., Sueoka E., Kimura S. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 2012, 75:89-94.
30. Tachibana K., Minami Y., Shiba-Ishii A., Kano J., Nakazato Y., Sato Y., Goya T., Noguchi M. Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. Lung Cancer 2012, 75:181-188.
31. Tsao M.S., Liu N., Chen J.R., Pappas J., Ho J., To C., Viallet J., Park M., Zhu H. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 1998, 20:1-16.
32. Gumustekin M., Kargi A., Bulut G., Gozukizil A., Ulukus C., Oztop I., Atabey N. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol. Oncol. Res. 2012, 18:209-218.
33. Noro R., Seike M., Zou F., Soeno C., Matsuda K., Sugano T., Nishijima N., Matsumoto M., Kitamura K., Kosaihira S., Minegishi Y., Yoshimura A., Kubota K., Gemma A. MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation. BMC Cancer 2015, 15:31.